Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)

Overview

About this study

The purpose of this study is to determine if the use of image-guided, endovascular therapy (EVT) is an effective strategy with which to reduce Post Thrombotic Syndrome (PTS) disease severity and to improve quality of life in patients with established disabling iliac-obstructive post thrombotic syndrome (DIO-PTS).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Disabling (moderate-to-severe) PTS, defined by a) presence of chronic venous disease > 3 months duration in a leg with history of DVT, as determined by the site principal investigator or a physician co-investigator; and b) substantial limitation of daily activities or work capacity due to venous symptoms or an open venous ulcer, per the same investigator.
  • Ipsilateral iliac vein obstruction documented within 3 months prior to screening by either:
    • Occlusion or >50% stenosis of the iliac vein on venogram, CT venogram, MR venogram, or intravascular ultrasound (IVUS); or
    • Air plethysmography showing deep venous obstruction of the ipsilateral leg (reduced venous outflow fraction), and ultrasound showing echogenic material in the ipsilateral iliac vein and non-phasic continuous Doppler flow in the ipsilateral common femoral vein (CFV) in the presence of normal phasic Doppler flow in the contralateral CFV.

Exclusion Criteria:

  • Age less than 18 years.
  • Acute ipsilateral proximal DVT episode within the last 3 months, or acute contralateral DVT for which thrombolytic therapy is planned.
  • Lack of suitable inflow into the ipsilateral common femoral vein per the treating physician.
  • Previous stent placement in the infrarenal IVC or ipsilateral iliac or common femoral vein.
  • Absence of PTS of at least moderate severity.
  • Chronic arterial limb ischemia (ankle-brachial index < 0.5 within the previous 1 month) in the ipsilateral leg (if peripheral arterial disease is present or suspected, an ankle-brachial index should be obtained and documented).
  • Presence of open venous ulcer > 50 cm2 area, suspicion for active ulcer infection, or visualization of bone or tendon within the ulcer in the ipsilateral leg.
  • Inability to tolerate endovascular procedure due to acute illness, or general health.
  • Severe allergy to iodinated contrast refractory to steroid premedication.
  • Known allergy to stent or catheter components.
  • Hemoglobin < 8.0 g/dl, uncorrectable INR > 3.05, or platelet count < 75,000/ml.
  • Severe renal impairment (on chronic dialysis or estimated GFR < 30 ml/min).
  • Disseminated intravascular coagulation or other major bleeding diathesis.
  • Pregnancy (positive pregnancy test).
  • Life-expectancy < 6 months or chronically non-ambulatory for reasons other than PTS.
  • Inability to provide informed consent or to comply with study assessments.
    • Note:  patients who initially meet an exclusion criterion can have eligibility re-evaluated on a subsequent occasion.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 12/15/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Newton Neidert, M.D.

Open for enrollment

Contact information:

Newton Neidert M.D.

Neidert.Newton@mayo.edu

More information

Publications

Publications are currently not available